Fig. 2

Subgroups of Early and Late Relapsers compared at the time of diagnosis to relapse. (A) In early relapsers of the Staal dataset (n = 19) 12 genes were overexpressed at time of relapse (gray bars, P = .371) versus time of diagnosis (black bars). 2 genes were individually significant ERCC8 (P = .042) and ERCC6 (P = .019). (B) In early relapsers of the Hogan dataset (n = 27), 4 genes had an increased in gene expression. The pathway was significantly under-expressed (P = .007). No genes were significantly overexpressed. (C) In the combined early relapsers dataset (n = 46), 7 genes were upregulated at the time of recurrence (P = .180). (D) In the late relapsers of the Staal dataset (n = 8) 16 NER genes were upregulated at the time of relapse versus diagnosis (P = 0.007). 7 genes were individually significantly overexpressed, CCNH (P = .044), GTF2H4 (P = .049), RPA1 (P = .030), ERCC1 (P = .035), GTF2H2 (P = .033), RAD23B (P = .040), ERCC3 (P = .034). In the late relapsers of the Hogan dataset (n = 22), 16 genes were overexpressed (p = .007). 8 genes were individually significantly overexpressed, DDB1 (P = .003), ERCC2 (P = .021), ERCC1 (P = .015), DDB2 (P < .001), RPA2 (P = .005), RPA1 (P = .004), GTF2H3 (P < .001), and RPA3 (P < .001). (F) In the late relapsers of the combined dataset (n = 30), 16 genes were overexpressed at recurrence (P = .007) versus diagnosis. 11 genes showed significantly increased expression at relapse: ERCC5 (P = .035), GTF2H4 (P = .025), ERCC2 (P = .013), ERCC3 (P = .016), GTF2H2 (P = .012), DDB1 (P < .001), DDB2 (P < .001), ERCC1 (P < .001), RPA3 (P < .001), RPA2 (P < .001), and RPA1 (P < .001). * indicates P < .05 in a one tailed t-test